rTMS and tDCS for the treatment of catatonia: A systematic review
- PMID: 32600779
- DOI: 10.1016/j.schres.2020.05.028
rTMS and tDCS for the treatment of catatonia: A systematic review
Abstract
Background: Catatonia is a potentially life threatening syndrome in various psychiatric disorders. As first line treatment, benzodiazepines and electroconvulsive therapy (ECT) are recommended. In some cases, benzodiazepines are ineffective and ECT is not available or contraindicated. Therefore, the search for new and alternative treatment strategies is of great importance.
Objective: To review the evidence for alternative neurostimulation treatment strategies (rTMS and tDCS) for catatonia according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
Method: We performed a systematic literature search in several electronic databases. We also searched the WHO International Clinical Trials Registry Platform (ICTRP) and the ClinicalTrials.gov database to detect registered studies.
Results: We identified nine publications on rTMS treatment and four publications on tDCS in catatonia. Most of the publications reported clinically relevant improvement of catatonic symptoms. Only two publications reported insufficient improvement. The available Bush-Francis Catatonia Rating Scale scores showed statistical significant improvement following rTMS and tDCS. We could not identify any finished clinical studies or case series, dedicated to this topic. We also could not identify any publications that compared first line treatment options with rTMS or tDCS.
Conclusions: Based on the case report literature, rTMS and tDCS might be promising alternative treatment strategies for patients who do not respond to benzodiazepines or in case ECT is not available or contraindicated. There are even hints that rTMS or tDCS might be an option in patients who respond to ECT but need long-term treatment to control catatonic symptoms. Further clinical trials are needed to allow for an evidence-based evaluation of potential risks and benefits of rTMS and tDCS for catatonia.
Keywords: Catatonia; Review; rTMS; tDCS.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest MH, EW, AR and DK report no conflicts of interest. WS has received a speaker's honorarium from Mag&More GmbH. AH is editor of the German S3-guideline schizophrenia and the WFSBP guidelines schizophrenia. He has received a paid speakership from Janssen-Cilag, Otsuka and Lundbeck. He was member of an advisory board of Roche, Janssen-Cilag, Otsuka and Lundbeck. FP is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and has received speaker's honoraria from Mag&More GmbH and the neuroCare Group. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, and Mag&More GmbH and Brainsway Inc., Jerusalem, Israel. PF has received research support/honoraria for lectures or advisory activities from Abbott, Boehringer-Ingelheim, Janssen, Essex, Lundbeck, Otsuka, Recordati, Richter, Servier and Takeda.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
